Surgical practice patterns following NCCTG N0338 "Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer."

被引：0
|
作者：
Apsey, H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Roy, V. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Pockaj, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Northfelt, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Sticca, R. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Nikcevich, D. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Mattar, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Fitch, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Perez, E. A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Mayo Clin Arizona, Phoenix, AZ USA
[2] Mayo Clin Minnesota, Rochester, MN USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
[4] Univ N Dakota, Grand Forks, ND 58201 USA
[5] Duluth Clin, Duluth, MN USA
[6] Wichita Community Clin Oncol Program, Wichita, KS USA
[7] Mayo Clin Florida, Jacksonville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
623
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Docetaxel and cisplatin as induction chemotherapy in stage IIIA N2 non-small cell lung cancer (NSCLC): An EORTC phase II trial (08984).
    Manegold, C
    Biesma, B
    Smit, H
    Van Meerbeeck, J
    Debruyne, C
    Legrand, C
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 657S - 657S
  • [42] Results from a Single Institution Phase II Trial of Concurrent Docetaxel/Carboplatin/Radiotherapy Followed by Surgical Resection and Consolidation Docetaxel/Carboplatin in Stage III Non-Small-Cell Lung Cancer
    Das, Millie
    Donington, Jessica S.
    Murphy, James
    Kozak, Margaret
    Eclov, Neville
    Whyte, Richard I.
    Hoang, Chuong D.
    Zhou, Lisa
    Le, Quynh-Thu
    Loo, Billy W., Jr.
    Wakelee, Heather
    CLINICAL LUNG CANCER, 2011, 12 (05) : 280 - 285
  • [43] A Phase I-II Trial of Ispinesib, a Kinesin Spindle Protein Inhibitor, Dosed Every Two Weeks as First Line Chemotherapy for Advanced Locally Recurrent or Metastatic Breast Cancer.
    Gomez, H.
    Philco, M.
    Pimentel, P.
    Escandon, R.
    Saikali, K.
    Seroogy, J.
    Wolff, A.
    Conlan, M.
    CANCER RESEARCH, 2009, 69 (24) : 857S - 857S
  • [44] Interim analysis findings from a phase III randomized trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for stage II/III breast cancer (BC)
    Ahn, Joong-Bae
    Oh, Jung-Hye
    Kwon, Youngmee
    Chung, Ki-Wook
    Kang, Han-Sung
    Shin, Kyung Hwan
    Kim, Eun-A
    Lee, Eun Sook
    Ro, Jungsil
    ANNALS OF ONCOLOGY, 2004, 15 : 57 - 57
  • [45] Analysis of prognostic factors after 16 years of follow-up in a randomized phase II trial of neoadjuvant FAC compared with CMF in stage III breast cancer.
    Leone, Julieta
    Pablo Leone, Jose
    Teodoro Vallejo, Carlos
    Eduardo Perez, Juan
    Omar Romero, Alberto
    Raul Machiavelli, Mario
    Romero Acuna, Luis
    Ester Dominguez, Maria
    Langui, Mario
    Margot Fasce, Hebe
    Amadeo Leone, Bernardo
    Ortiz, Eduardo
    Iturbe, Julian
    Osvaldo Zwenger, Ariel
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [46] A Prospective Phase I trial of Concurrent Cisplatin (CIS) and Radiation Therapy (RT) in Women with Stage II and III Triple-negative Breast Cancer (TNBC)
    Bellon, J. R.
    Chen, Y. H.
    Rees, R.
    Taghian, A. G.
    Wong, J. S.
    Punglia, R. S.
    Shiloh, R.
    Krishnan, M. S.
    Andrews, C.
    Isakoff, S. J.
    Winer, E.
    Tolaney, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S43 - S43
  • [47] Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial
    Shi, Qiyun
    Qi, Xiaowei
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Wang, Shushu
    Zhang, Guozhi
    Wang, Mengyuan
    Che, Hongying
    Lv, Pengwei
    Chen, Dejie
    Hu, Jinhui
    Li, Qiuyun
    Zhang, Yanwu
    Yu, Qiao
    Yang, Kunxian
    Zhong, Yuan
    Chen, Chuang
    Zhou, Zemin
    Qian, Liyuan
    Zhang, Jingwei
    Ma, Mingde
    Sun, Yi
    Liu, Jiangbo
    Zhang, Yi
    Jiang, Jun
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC).
    Lee, KS
    Lee, ES
    Kwon, YM
    Nam, BH
    Kwon, HS
    Chung, KW
    Kang, HS
    Kim, EA
    Kim, SW
    Ro, J
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S224 - S224
  • [49] Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01
    Im, Seock-Ah
    Lee, Keun Seok
    Ro, Jungsil
    Lee, Eun Sook
    Kwon, Youngmee
    Ahn, Jin-Hee
    Ahn, Jin Seok
    Kim, Jee Hyun
    Kang, Han Sung
    Shin, Kyung Hwan
    Noh, Dong-Young
    Park, In-Ae
    Kim, Sung-Bae
    Im, Young Hyuck
    Ha, Sung Whan
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (02) : 589 - 600
  • [50] Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01
    Seock-Ah Im
    Keun Seok Lee
    Jungsil Ro
    Eun Sook Lee
    Youngmee Kwon
    Jin-Hee Ahn
    Jin Seok Ahn
    Jee Hyun Kim
    Han Sung Kang
    Kyung Hwan Shin
    Dong-Young Noh
    In-Ae Park
    Sung-Bae Kim
    Young Hyuck Im
    Sung Whan Ha
    Breast Cancer Research and Treatment, 2012, 132 : 589 - 600
12345